The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection
- PMID: 8523580
- PMCID: PMC189854
- DOI: 10.1128/JVI.70.1.612-616.1996
The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection
Abstract
We have previously demonstrated that two mouse cell lines that are poorly infectible by reovirus become highly susceptible upon transfection with the gene encoding the epidermal growth factor receptor (EGFR) (J. E. Strong, D. Tang, and P. W. K. Lee, Virology 197:405-411, 1993). This enhancement of infection efficiency requires a functional EGFR, since such an enhancement is not observed in cells expressing a mutated (kinase-inactive) EGFR. The additional finding that reovirus is capable of directly binding to the N-terminal ectodomain of the EGFR (D. Tang, J. E. Strong, and P. W. K. Lee, Virology 197:412-414, 1993) has led us to question whether this interaction is required for the activation of a signalling cascade that somehow augments the ensuing infection process. In the present study, we address this question, using cells transfected with the v-erbB oncogene, which encodes a protein structurally related to the EGFR but lacking a large portion of the N-terminal ligand-binding domain. The v-erbB protein also possesses ligand-independent, constitutive tyrosine kinase activity. Control NIH 3T3 cells, which are poorly infectible by reovirus (serotype 3, strain Dearing), and NIH 3T3 cells transfected with the v-erbB oncogene (THC-11) were assayed for their susceptibilities to reovirus infection. Infectivity was determined by immunofluorescent detection of viral proteins, sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of radiolabeled cells, and plaque titration. All three assays demonstrated a drastically higher degree of susceptibility to infection in the THC-11 cell line. This enhanced susceptibility was found to be abrogated by treatment of the cells with genistein, an inhibitor of tyrosine protein kinases, but only partially by treatment with daidzein, an inactive analog of genistein. We propose that the mechanism of enhancement of infection efficiency conferred by EGFR and v-erbB is through the opportunistic utilization by the virus of an already activated signal transduction pathway.
Similar articles
-
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.Cancer Res. 2003 Dec 15;63(24):8930-8. Cancer Res. 2003. PMID: 14695210
-
Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling.Curr Biol. 2002 Aug 20;12(16):1386-94. doi: 10.1016/s0960-9822(02)01070-9. Curr Biol. 2002. PMID: 12194819
-
Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.Oncogene. 2004 Oct 14;23(47):7810-20. doi: 10.1038/sj.onc.1208055. Oncogene. 2004. PMID: 15361836
-
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.Exp Cell Res. 2003 Mar 10;284(1):111-21. doi: 10.1016/s0014-4827(02)00096-4. Exp Cell Res. 2003. PMID: 12648470 Review.
-
Emerging therapies in gastrointestinal cancers.World J Gastroenterol. 2006 Dec 14;12(46):7440-50. doi: 10.3748/wjg.v12.i46.7440. World J Gastroenterol. 2006. PMID: 17167831 Free PMC article. Review.
Cited by
-
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.Int J Mol Sci. 2024 Jan 18;25(2):1180. doi: 10.3390/ijms25021180. Int J Mol Sci. 2024. PMID: 38256250 Free PMC article. Review.
-
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. doi: 10.1016/j.cytogfr.2010.02.006. Epub 2010 Mar 12. Cytokine Growth Factor Rev. 2010. PMID: 20223697 Free PMC article. Review.
-
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.J Clin Invest. 2010 May;120(5):1551-60. doi: 10.1172/JCI41431. Epub 2010 Apr 1. J Clin Invest. 2010. PMID: 20364090 Free PMC article.
-
Modulation of Reoviral Cytolysis (II): Cellular Stemness.Viruses. 2023 Jun 29;15(7):1473. doi: 10.3390/v15071473. Viruses. 2023. PMID: 37515162 Free PMC article.
-
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Cancer. 2016 Mar 15;122(6):875-83. doi: 10.1002/cncr.29856. Epub 2015 Dec 28. Cancer. 2016. PMID: 26709987 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous